Considering the potential differences in the pharmacological mechanism of diverse CDK4/6 inhibitors, further exploration of the mechanism of GPER and resistance to various CDK4/6 inhibitors is expected to improve the prognosis of HR+ BC. This evidence concerns the gene GPER1 and breast cancer.